SoftBank Vision Fund led a series B round for the cancer therapy developer that was also backed by GV and Alexandria Venture Investments.

Relay Therapeutics, a US-based developer of protein-focused medicines, closed a $400m series B round led by SoftBank Vision Fund, the $98.6bn fund run by telecommunications firm Softbank, yesterday. GV, an early-stage investment vehicle for internet technology group Alphabet, also took part in the round, as did Alexandria Venture Investments, the strategic investment division of life…

The rest of this content is only accessible to Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.